How applicable is the single-dose AMBITION regimen for HIV-associated cryptococcal meningitis to high-income settings?. Harrison, T. S, Lawrence, D. S, Mwandumba, H. C, Boulware, D. R, Hosseinipour, M. C, Lortholary, O., Meintjes, G., Mosepele, M., & Jarvis, J. N Clinical Infectious Diseases, sep, 2022. ![How applicable is the single-dose AMBITION regimen for HIV-associated cryptococcal meningitis to high-income settings? [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex The AMBITION-cm phase III randomized controlled trial, conducted in east and southern Africa, showed that a single high dose (10 mg/kg) of liposomal amphotericin B, given with an optimized oral backbone of fluconazole and flucytosine, was non-inferior to the World Health Organization (WHO)-recommended regimen of seven days of amphotericin B deoxycholate plus flucytosine for treatment of HIV-associated cryptococcal meningitis, and has been incorporated into updated WHO treatment guidelines. We believe the trial findings also have important implications for the treatment of HIV-associated cryptococcal meningitis in high-income settings. We advance the arguments, supported by evidence where available, that the AMBITION-cm study regimen is likely to be (i) as fungicidal as the currently recommended 14-day liposomal amphotericin based treatments, (ii) better tolerated with fewer adverse effects, and (iii) confer significant economic and practical benefits, therefore should be included as a treatment option in guidance for HIV-associated cryptococcal treatment in high-income country settings.
@article{Harrison2022,
abstract = {The AMBITION-cm phase III randomized controlled trial, conducted in east and southern Africa, showed that a single high dose (10 mg/kg) of liposomal amphotericin B, given with an optimized oral backbone of fluconazole and flucytosine, was non-inferior to the World Health Organization (WHO)-recommended regimen of seven days of amphotericin B deoxycholate plus flucytosine for treatment of HIV-associated cryptococcal meningitis, and has been incorporated into updated WHO treatment guidelines. We believe the trial findings also have important implications for the treatment of HIV-associated cryptococcal meningitis in high-income settings. We advance the arguments, supported by evidence where available, that the AMBITION-cm study regimen is likely to be (i) as fungicidal as the currently recommended 14-day liposomal amphotericin based treatments, (ii) better tolerated with fewer adverse effects, and (iii) confer significant economic and practical benefits, therefore should be included as a treatment option in guidance for HIV-associated cryptococcal treatment in high-income country settings.},
author = {Harrison, Thomas S and Lawrence, David S and Mwandumba, Henry C and Boulware, David R and Hosseinipour, Mina C and Lortholary, Olivier and Meintjes, Graeme and Mosepele, Mosepele and Jarvis, Joseph N},
doi = {10.1093/CID/CIAC792},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Harrison et al. - 2022 - How applicable is the single-dose AMBITION regimen for HIV-associated cryptococcal meningitis to high-income se.pdf:pdf},
issn = {1058-4838},
journal = {Clinical Infectious Diseases},
keywords = {OA,fund{\_}not{\_}ack,original},
mendeley-tags = {OA,fund{\_}not{\_}ack,original},
month = {sep},
pages = {ciac792},
pmid = {36166405},
title = {{How applicable is the single-dose AMBITION regimen for HIV-associated cryptococcal meningitis to high-income settings?}},
url = {https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac792/6724283},
year = {2022}
}
Downloads: 0
{"_id":"xxevo48TaN8Ahz6kJ","bibbaseid":"harrison-lawrence-mwandumba-boulware-hosseinipour-lortholary-meintjes-mosepele-etal-howapplicableisthesingledoseambitionregimenforhivassociatedcryptococcalmeningitistohighincomesettings-2022","author_short":["Harrison, T. S","Lawrence, D. S","Mwandumba, H. C","Boulware, D. R","Hosseinipour, M. C","Lortholary, O.","Meintjes, G.","Mosepele, M.","Jarvis, J. N"],"bibdata":{"bibtype":"article","type":"article","abstract":"The AMBITION-cm phase III randomized controlled trial, conducted in east and southern Africa, showed that a single high dose (10 mg/kg) of liposomal amphotericin B, given with an optimized oral backbone of fluconazole and flucytosine, was non-inferior to the World Health Organization (WHO)-recommended regimen of seven days of amphotericin B deoxycholate plus flucytosine for treatment of HIV-associated cryptococcal meningitis, and has been incorporated into updated WHO treatment guidelines. We believe the trial findings also have important implications for the treatment of HIV-associated cryptococcal meningitis in high-income settings. We advance the arguments, supported by evidence where available, that the AMBITION-cm study regimen is likely to be (i) as fungicidal as the currently recommended 14-day liposomal amphotericin based treatments, (ii) better tolerated with fewer adverse effects, and (iii) confer significant economic and practical benefits, therefore should be included as a treatment option in guidance for HIV-associated cryptococcal treatment in high-income country settings.","author":[{"propositions":[],"lastnames":["Harrison"],"firstnames":["Thomas","S"],"suffixes":[]},{"propositions":[],"lastnames":["Lawrence"],"firstnames":["David","S"],"suffixes":[]},{"propositions":[],"lastnames":["Mwandumba"],"firstnames":["Henry","C"],"suffixes":[]},{"propositions":[],"lastnames":["Boulware"],"firstnames":["David","R"],"suffixes":[]},{"propositions":[],"lastnames":["Hosseinipour"],"firstnames":["Mina","C"],"suffixes":[]},{"propositions":[],"lastnames":["Lortholary"],"firstnames":["Olivier"],"suffixes":[]},{"propositions":[],"lastnames":["Meintjes"],"firstnames":["Graeme"],"suffixes":[]},{"propositions":[],"lastnames":["Mosepele"],"firstnames":["Mosepele"],"suffixes":[]},{"propositions":[],"lastnames":["Jarvis"],"firstnames":["Joseph","N"],"suffixes":[]}],"doi":"10.1093/CID/CIAC792","file":":C$\\$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Harrison et al. - 2022 - How applicable is the single-dose AMBITION regimen for HIV-associated cryptococcal meningitis to high-income se.pdf:pdf","issn":"1058-4838","journal":"Clinical Infectious Diseases","keywords":"OA,fund_not_ack,original","mendeley-tags":"OA,fund_not_ack,original","month":"sep","pages":"ciac792","pmid":"36166405","title":"How applicable is the single-dose AMBITION regimen for HIV-associated cryptococcal meningitis to high-income settings?","url":"https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac792/6724283","year":"2022","bibtex":"@article{Harrison2022,\r\nabstract = {The AMBITION-cm phase III randomized controlled trial, conducted in east and southern Africa, showed that a single high dose (10 mg/kg) of liposomal amphotericin B, given with an optimized oral backbone of fluconazole and flucytosine, was non-inferior to the World Health Organization (WHO)-recommended regimen of seven days of amphotericin B deoxycholate plus flucytosine for treatment of HIV-associated cryptococcal meningitis, and has been incorporated into updated WHO treatment guidelines. We believe the trial findings also have important implications for the treatment of HIV-associated cryptococcal meningitis in high-income settings. We advance the arguments, supported by evidence where available, that the AMBITION-cm study regimen is likely to be (i) as fungicidal as the currently recommended 14-day liposomal amphotericin based treatments, (ii) better tolerated with fewer adverse effects, and (iii) confer significant economic and practical benefits, therefore should be included as a treatment option in guidance for HIV-associated cryptococcal treatment in high-income country settings.},\r\nauthor = {Harrison, Thomas S and Lawrence, David S and Mwandumba, Henry C and Boulware, David R and Hosseinipour, Mina C and Lortholary, Olivier and Meintjes, Graeme and Mosepele, Mosepele and Jarvis, Joseph N},\r\ndoi = {10.1093/CID/CIAC792},\r\nfile = {:C$\\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Harrison et al. - 2022 - How applicable is the single-dose AMBITION regimen for HIV-associated cryptococcal meningitis to high-income se.pdf:pdf},\r\nissn = {1058-4838},\r\njournal = {Clinical Infectious Diseases},\r\nkeywords = {OA,fund{\\_}not{\\_}ack,original},\r\nmendeley-tags = {OA,fund{\\_}not{\\_}ack,original},\r\nmonth = {sep},\r\npages = {ciac792},\r\npmid = {36166405},\r\ntitle = {{How applicable is the single-dose AMBITION regimen for HIV-associated cryptococcal meningitis to high-income settings?}},\r\nurl = {https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac792/6724283},\r\nyear = {2022}\r\n}\r\n","author_short":["Harrison, T. S","Lawrence, D. S","Mwandumba, H. C","Boulware, D. R","Hosseinipour, M. C","Lortholary, O.","Meintjes, G.","Mosepele, M.","Jarvis, J. N"],"key":"Harrison2022","id":"Harrison2022","bibbaseid":"harrison-lawrence-mwandumba-boulware-hosseinipour-lortholary-meintjes-mosepele-etal-howapplicableisthesingledoseambitionregimenforhivassociatedcryptococcalmeningitistohighincomesettings-2022","role":"author","urls":{"Paper":"https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac792/6724283"},"keyword":["OA","fund_not_ack","original"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-JLqZ7RwZ3VC2d6ErLGHAtOeMRS_7GCz","dataSources":["Krmt6gt9ktB2s6ARh"],"keywords":["oa","fund_not_ack","original"],"search_terms":["applicable","single","dose","ambition","regimen","hiv","associated","cryptococcal","meningitis","high","income","settings","harrison","lawrence","mwandumba","boulware","hosseinipour","lortholary","meintjes","mosepele","jarvis"],"title":"How applicable is the single-dose AMBITION regimen for HIV-associated cryptococcal meningitis to high-income settings?","year":2022}